N. Hindi

P. Georg, P. Navarria, D. Campanacci, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Management of Synovial Sarcoma and Myxoid Liposarcoma.

R. Haas, N. Hindi, 2022, Surgical oncology clinics of North America.

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

J. Martín-Broto, A. Obrador-Hevia, C. Valverde, 2018, Clinical Cancer Research.

Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply.

J. Martín-Broto, D. Moura, N. Hindi, 2019, The Lancet. Oncology.

CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study

J. Martín-Broto, J. López-Guerrero, M. Tarón, 2020, Cancers.

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving ﬁrst-line chemotherapy An

S. Sleijfer, J. Blay, E. Wardelmann, 2018 .

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

J. Blay, A. Italiano, A. Le Cesne, 2022, Cancers.

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

J. Blay, J. Dopazo, A. Italiano, 2019, The Lancet. Oncology.

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.

J. Blay, J. Dopazo, E. de Álava, 2020, The Lancet. Oncology.

Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor

J. Martín-Broto, N. Hindi, 2016, Current opinion in oncology.

SELNET Clinical practice guidelines for bone sarcoma.

R. Maki, A. D. Dei Tos, J. Martín-Broto, 2022, Critical reviews in oncology/hematology.

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

J. Martín-Broto, C. Valverde, V. Martínez-Marín, 2022, Nature Communications.

Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II.

J. Martín-Broto, A. Redondo, N. Hindi, 2021, Cancer treatment reviews.

Experience with second-line trabectedin in daily clinical practice: case studies.

A. Le Cesne, J. Martín-Broto, G. Grignani, 2022, Future oncology.

Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression

J. Martín-Broto, D. Moura, N. Hindi, 2023, International journal of molecular sciences.

Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic

F. Alongi, S. Corradini, C. Salembier, 2020, The Lancet Oncology.

Gr upSM Systemic Treatment for Advanced Soft Tissue Sarcoma beyond Doxorubicin and Ifosfamide

J. Martín-Broto, N. Hindi, 2016 .

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group

P. A. Gardner, A. Caraceni, S. Boriani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups

J. Blay, A. Italiano, A. D. Dei Tos, 2019, EClinicalMedicine.

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

C. Antonescu, J. Desai, J. Fletcher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S. Sleijfer, S. Bonvalot, O. Mir, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.

A. D. Dei Tos, P. Casali, A. Gronchi, 2019, The oncologist.

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.

J. Blay, O. Mir, A. Italiano, 2018, The oncologist.

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study

J. Martín-Broto, A. Obrador-Hevia, J. López-Guerrero, 2020, Cancers.

Gastrointestinal stromal tumors (GISTs): SEAP–SEOM consensus on pathologic and molecular diagnosis

J. Martín-Broto, C. Serrano, J. López-Guerrero, 2017, Clinical and Translational Oncology.

ISG15 as a prognostic biomarker in solitary fibrous tumour

R. Maestro, J. Martín-Broto, J. García-Foncillas, 2022, Cellular and Molecular Life Sciences.

Pharmacokinetic food-effect study of abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC): The ABIFOOD trial (EudraCt number: 2012-003226-25).

L. Paz-Ares, I. Durán, M. Espinosa, 2016 .

Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial

J. Blay, J. Dopazo, J. Coindre, 2021, Molecular Cancer Therapeutics.

Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)

Robin L. Jones, J. Blay, F. Grosso, 2019, Clinical Cancer Research.

Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature

Robin L. Jones, L. Mariani, T. Chen, 2021, Cancer medicine.

Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center

J. Martín-Broto, D. Moura, N. Hindi, 2020, Cancers.

Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?

J. Martín-Broto, D. Moura, N. Hindi, 2019, Future oncology.

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study

Robin L. Jones, J. Blay, S. Litière, 2020, ESMO Open.

Response of conventional chondrosarcoma to gemcitabine alone: a case report

P. Casali, C. Morosi, S. Stacchiotti, 2015, Clinical Sarcoma Research.

Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

C. Antonescu, A. Caraceni, S. Bonvalot, 2021, ESMO open.

In Reply.

J. Martín-Broto, N. Hindi, 2019, The oncologist.

1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)

C. Valverde, J. López-Martín, J. Broto, 2020 .

Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.

J. Blay, J. Coindre, A. Italiano, 2020, JAMA oncology.

A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin

J. Dopazo, J. Martín-Broto, C. Romagosa, 2021, Molecular oncology.

IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.

E. Álava, S. Stacchiotti, J. López-Martín, 2018 .

A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).

Robin L. Jones, A. Italiano, A. D. Dei Tos, 2023, European journal of cancer.

Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.

P. Casali, S. Stacchiotti, N. Hindi, 2016, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

1450PSYSTEMIC THERAPY IN PERIVASCULAR EPITHELIOID CELL TUMORS (PECOMA).

A. D. Dei Tos, P. Casali, A. Marrari, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of p53 as a biomarker of pazopanib efficacy in solitary fibrous tumours: translational analysis of a phase II trial

J. Martín-Broto, S. Stacchiotti, B. Vincenzi, 2022, Therapeutic advances in medical oncology.

A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report

F. Rojo, C. Fletcher, J. Martín-Broto, 2021, International journal of molecular sciences.

What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?

J. Martín-Broto, N. Hindi, 2021, Current opinion in oncology.

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).

J. Martín-Broto, C. Valverde, A. de Juan, 2018, The oncologist.

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)

C. Valverde, N. Hindi, A. López-pousa, 2016, Clinical and Translational Oncology.

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

J. Dopazo, E. de Álava, J. Martín-Broto, 2020, Journal for ImmunoTherapy of Cancer.

International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.

J. Blay, E. Álava, A. Italiano, 2017 .

Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.

J. Blay, E. Álava, A. Italiano, 2017 .

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.

J. Carles, J. Arribas, S. Landolfi, 2018, The oncologist.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients

J. Martín-Broto, C. Serrano, J. López-Guerrero, 2018, Oncotarget.

GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma

C. Romagosa, C. Valverde, R. Vergés, 2021, Clinical and Translational Oncology.

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

J. Mora, J. Martín-Broto, A. Carnero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Foot pain: uncommon presentation of lung cancer

A. Lamarca, N. Hindi, C. Belda-Iniesta, 2012, BMJ Case Reports.

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas

J. Martín-Broto, C. Castilla, J. L. Mondaza-Hernandez, 2022, International journal of molecular sciences.

1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

A. Italiano, B. Vincenzi, C. Serrano, 2021, Annals of Oncology.

Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma

O. Myklebost, S. Behjati, A. Degasperi, 2018, Clinical Sarcoma Research.

Sunitinib malate in advanced alveolar soft part sarcoma (ASPS): A final update after the closure of the named use program.

P. Casali, T. Negri, S. Pilotti, 2015 .

Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.

J. Blay, A. Italiano, A. D. Dei Tos, 2023, JAMA oncology.

Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.

J. Blay, W. Tap, P. Rutkowski, 2021 .

Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)

A. Redondo, N. Hindi, A. Manzano, 2023, Cancers.

Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase II trial in localized myxoid liposarcoma—A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study.

J. Blay, A. Gronchi, C. Morosi, 2020 .

IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- soft-tissue sarcoma cohort

E. Álava, S. Stacchiotti, C. Valverde, 2019, Annals of Oncology.

IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.

E. Álava, P. Casali, P. Picci, 2020 .

Local Therapies for Metastatic Sarcoma: Why, When, and How?

K. Hong, P. Hohenberger, N. Hindi, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).

Robin L. Jones, A. Italiano, A. D. Dei Tos, 2023, European journal of cancer.

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

J. Martín-Broto, A. Carnero, Marco Pérez, 2023, Signal transduction and targeted therapy.

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups

J. Blay, A. Italiano, A. D. Dei Tos, 2019, EClinicalMedicine.

Erratum: Hindi, N., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers 2020, 12, 3740

J. Martín-Broto, D. Moura, N. Hindi, 2021, Cancers.

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

J. Blay, A. Italiano, J. Martín-Broto, 2023, Molecular Cancer.

Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

J. Martín-Broto, A. Trama, S. Piperno-Neumann, 2024, The Lancet regional health. Europe.